Sugiura D, Maruhashi T, Okazaki I, Shimizu K, Maeda T, Takemoto T, et al. Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science. 2019;364:558-566 pubmed publisher

Böttcher J, Bonavita E, Chakravarty P, Blees H, Cabeza Cabrerizo M, Sammicheli S, et al. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. Cell. 2018;172:1022-1037.e14 pubmed publisher

Secl xec L, Infante L, Nocchi L, De Lucia M, Cotugno G, Leoni G, et al. Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity. J Immunother Cancer. 2023;11: pubmed publisher

Xu H, Li Z, Kuo C, G xf6 tz K, Look T, de Toledo M, et al. A lncRNA identifies Irf8 enhancer element in negative feedback control of dendritic cell differentiation. elife. 2023;12: pubmed publisher

Rocca Y, Voissi xe8 re A, Valladeau Guilemond J, Bendriss Vermare N. Isolation and Identification of Dendritic Cell Subsets from Human and Mouse Tumors. Methods Mol Biol. 2023;2618:187-197 pubmed publisher

Liu L, Hou Y, Deng C, Tao Z, Chen Z, Hu J, et al. Single cell sequencing reveals that CD39 inhibition mediates changes to the tumor microenvironment. Nat Commun. 2022;13:6740 pubmed publisher

Wu R, Ohara R, Jo S, Liu T, Ferris S, Ou F, et al. Mechanisms of CD40-dependent cDC1 licensing beyond costimulation. Nat Immunol. 2022;23:1536-1550 pubmed publisher

Backlund C, Holden R, Moynihan K, Garafola D, Farquhar C, Mehta N, et al. Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity. Proc Natl Acad Sci U S A. 2022;119:e2204078119 pubmed publisher

Gargaro M, Scalisi G, Manni G, Briseño C, Bagadia P, Durai V, et al. Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication. Immunity. 2022;55:1032-1050.e14 pubmed publisher

Flommersfeld S, B xf6 ttcher J, Ersching J, Flossdorf M, Meiser P, Pachmayr L, et al. Fate mapping of single NK cells identifies a type 1 innate lymphoid-like lineage that bridges innate and adaptive recognition of viral infection. Immunity. 2021;54:2288-2304.e7 pubmed publisher

Giampazolias E, Schulz O, Lim K, Rogers N, Chakravarty P, Srinivasan N, et al. Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity. Cell. 2021;184:4016-4031.e22 pubmed publisher

Huang X, Ferris S, Kim S, Choudhary M, Belk J, Fan C, et al. Differential usage of transcriptional repressor Zeb2 enhancers distinguishes adult and embryonic hematopoiesis. Immunity. 2021;54:1417-1432.e7 pubmed publisher

Bonavita E, Bromley C, Jönsson G, Pelly V, Sahoo S, Walwyn Brown K, et al. Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade. Immunity. 2020;53:1215-1229.e8 pubmed publisher

Gallizioli M, Miro Mur F, Otxoa de Amezaga A, Cugota R, Salas Perdomo A, Justicia C, et al. Dendritic Cells and Microglia Have Non-redundant Functions in the Inflamed Brain with Protective Effects of Type 1 cDCs. Cell Rep. 2020;33:108291 pubmed publisher

Hegde S, Krisnawan V, Herzog B, Zuo C, Breden M, Knolhoff B, et al. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Cancer Cell. 2020;37:289-307.e9 pubmed publisher

Bagadia P, Huang X, Liu T, Durai V, Grajales Reyes G, Nitschké M, et al. An Nfil3-Zeb2-Id2 pathway imposes Irf8 enhancer switching during cDC1 development. Nat Immunol. 2019;20:1174-1185 pubmed publisher

Liu J, Zhang X, Chen K, Cheng Y, Liu S, Xia M, et al. CCR7 Chemokine Receptor-Inducible lnc-Dpf3 Restrains Dendritic Cell Migration by Inhibiting HIF-1α-Mediated Glycolysis. Immunity. 2019;50:600-615.e15 pubmed publisher

Barry K, Hsu J, Broz M, Cueto F, Binnewies M, Combes A, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018;24:1178-1191 pubmed publisher